WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually condition progression or maybe the contributors are not able to tolerate the study drugs.88 These preclinical studies offer paradigms for foreseeable future clinical t